← FDA DRUG APPROVALS

FDA ANDA · ANDA203603

FLUDEOXYGLUCOSE F-18

Sponsor: CARDINAL HEALTH 414

APPLICATION
ANDA203603
TYPE
ANDA
ORIGINAL APPROVAL
2015-11-13
LATEST ACTION
2018-09-27
ROUTE
INTRAVENOUS
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Prescription

Products

FLUDEOXYGLUCOSE F18Prescription
FLUDEOXYGLUCOSE F-18 20-300mCi/ML · INJECTABLE · INTRAVENOUS
FLUDEOXYGLUCOSE F18Prescription
FLUDEOXYGLUCOSE F-18 20-500mCi/ML · INJECTABLE · INTRAVENOUS

Approval history

2018-09-27Manufacturing (CMC) · Supplement 7AP
2015-11-13UNKNOWN · OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →